Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy

This article was originally published in The Pink Sheet Daily

Executive Summary

Parallels to Novartis-Sandoz 2005 combination seen.

You may also be interested in...

Ranbaxy Management Would Likely Rebuf Any Pfizer Offer – Analysts

"It's hard to see how Pfizer would run the company," one analyst said in an interview.

Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs

Daiichi will pay $4.6 billion for stake in generics marketer.

Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations

Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts